Redmile Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Redmile Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-916,927	Closed	-$20.8M	–	62
2016 Q3	$20.8M	Sell	916,927 -549,610	-37%	-$12.9M	1.66%	23
2016 Q2	$34.6M	Buy	1,466,537 +576,930	+65%	+$14.2M	3.31%	11
2016 Q1	$18.1M	Sell	889,607 -68,548	-7%	-$2.17M	1.86%	21
2015 Q4	$49.3M	Buy	958,155 +188,514	+24%	+$9.14M	3.69%	10
2015 Q3	$32.8M	Buy	769,641 +616,941	+404%	+$29.8M	2.49%	18
2015 Q2	$6.96M	Buy	+152,700	New	+$6.14M	0.57%	43
2014 Q2	–	Sell	-452,194	Closed	-$11.7M	–	63
2014 Q1	$11.7M	Buy	+452,194	New	+$12.1M	1.4%	32

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group's PTLA Position: Q4 2016 in Review

Redmile Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2016, closing a stake of 916,927 shares — an estimated $20.8M sold.

Redmile Group first reported a position in PTLA in Q1 2014 and held it in 7 quarters. The position peaked at $49.3M in Q4 2015. 150 funds tracked by Wall St. Rank hold PTLA as of Q4 2016.

Redmile Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Redmile Group sold 916,927 Portola Pharmaceuticals, Inc. shares in Q4 2016, an estimated $20.8M.
Redmile Group first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 7 quarters.
Redmile Group's Portola Pharmaceuticals, Inc. position peaked at $49.3M in Q4 2015.
150 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2016.

Based on Redmile Group's 13F filing for Q4 2016, filed 14 Feb 2017.